Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> SBE-β-CD [182410-00-0]

SBE-β-CD [182410-00-0]

Imprimer Imprimer
Identifiez-vous

Référence HY-17031-5g

Conditionnement : 5g

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

SBE-β-CD est un dérivé de sulfobutyléther β-cyclodextrine utilisé comme excipient ou agent de formulation pour augmenter la solubilité d'agents peu solubles.

SBE-β-CD ist ein Sulfobutylether-β-Cyclodextrinderivat, das als Hilfsstoff oder Formulierungsmittel zur Erhöhung der Löslichkeit schwerlöslicher Mittel verwendet wird.

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative used as an excipient or a formulating agent to increase the solubility of poorly soluble agents.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

SBE-β-CD Chemical Structure

CAS No. : 182410-00-0

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

SBE-β-CD Related Antibodies

  • •Cell. 2021 Jul 22;184(15):4032-4047.e31.  [Abstract]
  • •Cancer Cell. 2020 Dec 14;38(6):844-856.e7.  [Abstract]
  • •Nat Med. 2017 Jun;23(6):723-732.  [Abstract]
  • •Nat Commun. 2024 Feb 14;15(1):1353.  [Abstract]
  • •Nat Commun. 2023 Oct 18;14(1):6584.  [Abstract]
  • •Adv Sci (Weinh). 2022 Nov 29;e2203718.  [Abstract]
  • •Sci Transl Med. 2021 Jan 20;13(577):eaba7401.  [Abstract]
  • •Nat Commun. 2019 Jul 1;10(1):2901.   [Abstract]
  • •Nat Commun. 2018 Jun 29;9(1):2547.  [Abstract]
  • •Theranostics. 2022 May 27;12(10):4581-4598.  [Abstract]
  • •Cancer Immunol Res. 2021 Apr 10;canimm.0968.2020.  [Abstract]
  • •J Exp Clin Cancer Res. 2021 Mar 26;40(1):113.  [Abstract]
  • •Theranostics. 2019 Nov 26;9(26):8426-8436.  [Abstract]
  • •Cancer Res. 2017 Jan 15;77(2):579-589.  [Abstract]
  • •Cell Rep. 2023 Apr 15;42(4):112396.  [Abstract]
  • •Mol Ther Nucleic Acids. 20 July 2022.
  • •Br J Cancer. 2022 May 21.  [Abstract]
  • •Cell Rep. 2020 Nov 17;33(7):108395.  [Abstract]
  • •Cell Rep. 2019 Oct 8;29(2):249-257.e8.   [Abstract]
  • •Metabolism. 2018 May;82:88-99.  [Abstract]
  • •Cancer Lett. 2016 Oct 10;381(1):14-22.  [Abstract]
  • •J Affect Disorders. 2024 Jan 12:S0165-0327(23)01543-4.  [Abstract]
  • •Transl Psychiatry. 2023 Oct 6;13(1):310.  [Abstract]
  • •Matrix Biol. 2023 Mar 12;S0945-053X(23)00035-5.  [Abstract]
  • •Phytother Res. 2022 Nov 3.  [Abstract]
  • •Matrix Biol. 2022 Aug 25;S0945-053X(22)00104-4.  [Abstract]
  • •Neurobiol Dis. 11 March 2022, 105689.
  • •Cell Death Discov. 2021 Dec 4;7(1):374.  [Abstract]
  • •Mucosal Immunol. 2020 Aug 18.  [Abstract]
  • •Cell Mol Life Sci. 2020 Aug 26.  [Abstract]
  • •Br J Pharmacol. 2018 Jan;175(1):84-99.  [Abstract]
  • •Int J Cancer. 2016 Feb 15;138(4):1024-32.  [Abstract]
  • •Sci Rep. 2023 May 11;13(1):7656.  [Abstract]
  • •Molecules. 2023 May 15, 28(10), 4096.
  • •Neurochem Res. 2022 Oct 15.  [Abstract]
  • •J Mol Liq. 9 September 2022, 120314.
  • •Front Pharmacol. 2022 Jan 10;12:792263.  [Abstract]
  • •J Am Heart Assoc. 2021 Jul 3;e019877.  [Abstract]
  • •Cell Immunol. 2021, 104384.
  • •Oncol Rep. 2019 Jan;41(1):447-454.  [Abstract]
  • •Front Pharmacol. 2018 Jan 30;9:25.  [Abstract]
  • •Int J Oncol. 2017 Aug;51(2):425-434.  [Abstract]
  • •Cancer Sci. 2016 May;107(5):638-43.  [Abstract]
  • •Sci Rep. 2015 Oct 30;5:15881.  [Abstract]
  • •J Ovarian Res. 2023 Nov 28;16(1):231.  [Abstract]
  • •RSC Adv. 2023 Sep 11;13(39):27244-27254.  [Abstract]
  • •PLoS One. 2023 Sep 14;18(9):e0291537.  [Abstract]
  • •Neuroscience. 2023 Jul 28;S0306-4522(23)00336-6.  [Abstract]
  • •Cereb Cortex. 2023 May 13;bhad166.  [Abstract]
  • •Mol Immunol. 21 October 2022.
  • •Neuropsychiatr Dis Treat. 2022 May 16;18:1027-1037.  [Abstract]
  • •Biochem Biophys Res Commun. 2018 Jun 18;501(1):9-15.  [Abstract]
  • •Biopharm Drug Dispos. 2018 Jan;39(1):30-37.  [Abstract]
  • •PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006104.  [Abstract]
  • •Oncol Lett. 2017 Dec;14(6):6863-6868.  [Abstract]
  • •Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8.  [Abstract]
  • •Biochem Biophys Res Commun. 2015 May 1;460(2):362-7.  [Abstract]
  • •World Neurosurg. 2021 Nov 24;S1878-8750(21)01796-4.  [Abstract]
  • •Research Square Preprint. 2024 Feb 22.
  • •bioRxiv. 2023 Oct 1.
  • •bioRxiv. 2023 Oct 10.
  • •Research Square Preprint. 2023 Sep 18.
  • •bioRxiv. 2023 Sep 16.
  • •University of Ottawa. 2023 Jun 12.
  • •Oxid Med Cell Longev. 2022 Dec 7;2022:3373828.  [Abstract]
  • •Patent. US20220380473A1.
  • •Research Square Print. 2022 Jun.
  • •Research Square Preprint. 2022 May.
  • •Patent. US20220002420A1.
  • •University of Cambridge. 2021 , e20.
  • •ETH Zurich. Institute of Fluid Dynamics. 2021 Apr.
  • •Patent. US20200385396A1.
  • •Patent. US20170290918A1.
  • •Departamento de Ciencias y Tecnología Farmacéuticas. Universidad de Chile. 2017.

  • Activité biologique

  • Protocole

  • Pureté et documentation

  • Références

  • Avis client

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative used as an excipient or a formulating agent to increase the solubility of poorly soluble agents.

In Vitro

SBE-β-CD is a chemically modified β-CD that is a cyclic hydrophilic oligosaccharide which is negatively charged in aqueous media. β-CD functioned is a solubilizer only at low concentrations, whereas SBE7-β-CD exhibits strong solubilizing effects over a wide concentration range.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SBE-β-CD Related Antibodies

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196  [Content Brief]

    [2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67  [Content Brief]

Rats
A 300 g rat is administered with 1 mL of a 0.1 M SBE-β-CD solution containing 5.64 mg of Compound 1, and assuming an extracellular volume of 90 mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation, Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance.

MCE n'a pas confirmé de manière indépendante l'exactitude de ces méthodes. Ils sont pour référence seulement.

  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196  [Content Brief]

    [2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67  [Content Brief]

  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196

    [2]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Others
  • Biochemical Assay Reagents
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SBE-β-CD182410-00-0Sulfobutylether-β-CyclodextrinBiochemical Assay ReagentsInhibitorinhibitorinhibit

Vos produits récemment consultés:

Demande en ligne

Your information is safe with us. * Required Fields.

Bulk Inquiry

Inquiry Information

Nom du produit:
SBE-β-CD
Cat. No.:
HY-17031
Quantité:
MCE Japan Authorized Agent:

Avis client

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

Vous serez peut-être également intéressé par les produits suivants :



Référence
Description
Cond.
Prix HT